Table 2.

Cancer treatment agents and the percentage of cases that received such agents per primary cancer site

Primary site	Platinum-based compounds	Antimetabolites	Taxanes	Anti-VEGF agents	Plant alkaloid and topoisomerase I inhibitor	Immunotherapy agents	Erythropoietin agents
Breast	7.7%	42.3%	61.5%	42.3%	-	3.9%	3.9%
GI	67.6%	92.6%	34.3%	35.2%	31.5%	1.9%	30.6%
Head and neck	85.7%	71.4%	42.9%	0.0%	0.0%	57.1%	14.3%
Lung	65.2%	13.6%	48.5%	22.7%	4.6%	60.6%	28.8%
Urinary system	41.7%	33.3%	29.2%	33.3%	-	33.3%	37.5%
Woman reproductive system	85.1%	25.5%	70.2%	74.5%	2.1%	-	36.2%
Other	53.9%	46.2%	53.9%	38.5%	7.7%	30.8%	23.1%
% in all patients	60.7%	50.7%	45.3%	37.6%	13.1%	19.8%	27.9%